Selva Therapeutics is a biotechnology company dedicated to the development of therapeutics for infectious diseases. Its lead drug candidate, SLV213, is an orally available small-molecule antiviral therapy with activity against a range of viruses, including SARS-CoV-2, the virus causing COVID-19.